PepEvolutionRetatrutide
A triple GIP/GLP-1/glucagon agonist showing >20% weight loss in phase 2 — the most powerful incretin in the pipeline.
Verdict — C · Emerging / Mixed
Unprecedented phase-2 weight-loss signal and strong phase-3 enrollment, but no approval, limited independent sourcing, and an expected GLP-1-class safety profile with additional glucagon-axis unknowns. Watch the TRIUMPH readout; buy nothing from the gray market.
Overview
Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist (Eli Lilly) currently in phase-3 TRIUMPH trials with no regulatory approval yet. Phase-2 data demonstrated up to 24% body-weight reduction — the largest in any published incretin trial. Gray-market supply exists but is unverified; the compound is not yet commercially manufactured for consumer use.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.